A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 180; no. 3; pp. 445 - 448
Main Authors Kirschbaum, Mark H., Frankel, Paul, Synold, Timothy W., Zain, Jasmine, Claxton, David, Tuscano, Joseph, Newman, Edward M., Gandara, David R., Lara, Primo N.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.02.2018
Subjects
California
Cancer
clinical trials
Hematology
Humans
Myelodysplastic syndrome
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - adverse effects
Recombinant Fusion Proteins - therapeutic use
Treatment Outcome
Vascular endothelial growth factor
myelodysplastic syndrome
vascular endothelial growth factor
clinical trials
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14333